Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sufentanil/triazolam sublingual - Talphera

Next Previous
Drug Profile

Sufentanil/triazolam sublingual - Talphera

Alternative Names: ARX-03; ARX-F03; sublingual sufentanil/triazolam NanoTab™; triazolam/sufentanil

Latest Information Update: 11 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AcelRx Pharmaceuticals
  • Developer Talphera
  • Class Benzodiazepines; General anaesthetics; Hypnosedatives; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action GABA A receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain; Sedation

Highest Development Phases

  • No development reported Procedural pain; Sedation

Most Recent Events

  • 09 Jan 2024 AcelRx Pharmaceuticals is now called Talphera
  • 02 Nov 2020 No development reported - Phase-II for Procedural pain in USA (Sublingual) in November 2020 (AcelRx Pharmaceuticals pipeline)
  • 02 Nov 2020 No development reported - Phase-II for Sedation in USA (Sublingual) in November 2020 (AcelRx Pharmaceuticals pipeline)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top